Cell Therapy Clinical Trials
Hub page covering approved-care and trial pathways. Some cell therapies are FDA-approved in specific diseases, while many other uses remain investigational and location-specific. FDA’s current cellular and gene therapy approvals include multiple CAR-T products, approved gene therapies for sickle cell disease and beta-thalassemia, and approved TIL therapy for advanced melanoma.
Cell therapy clinical trials matter because approved care does not cover every disease, every treatment line, or every target. Some patients come to this page because there is no approved cell-therapy option for their condition. Others come because they want to compare standard treatment with a trial pathway involving CAR-T, TIL therapy, or gene therapy.
Approved Care vs Trial-Only Care
Some cell-therapy pathways are already part of approved care in specific settings. FDA’s approved cellular and gene therapy product list includes multiple autologous CAR-T products for selected blood cancers, approved gene therapies such as Casgevy and Lyfgenia for sickle cell disease and Casgevy and Zynteglo for transfusion-dependent beta-thalassemia, and Amtagvi for advanced melanoma.
But approval in one setting does not make the whole field approved. A patient may read about CAR-T, TIL, or gene therapy online and still find that their own disease, timing, or location only fits a clinical trial. That is especially true in AML, most solid-tumor CAR-T programs, most non-melanoma TIL programs, and many next-generation or dual-target constructs.
Trial options differ by therapy type, and many studies focus on questions that go beyond current FDA-approved uses.
- CAR-T trials: CAR-T trials usually focus on one of four patterns: diseases without approved CAR-T options, earlier-line treatment questions, new targets or dual-target constructs, or post-approved-care strategies. FDA’s approved CAR-T landscape is still centered on selected blood cancers, so many trial programs explore what happens beyond those approved labels.
- TIL trials: TIL therapy has one current FDA-approved setting in advanced melanoma through Amtagvi. Outside melanoma, most TIL use remains investigational and usually belongs on a trial page rather than an approved-care page.
- Gene-therapy trials: Gene therapy includes both approved and trial-stage pathways. FDA has approved gene therapies for sickle cell disease and beta-thalassemia, but many other gene-therapy questions still sit in the research space, including newer products, safety follow-up strategies, and broader disease applications.
How to Read Inclusion and Exclusion Criteria
A useful trial review usually starts with the same core questions:
Does the diagnosis and subtype match the study?
Has the patient already had the required prior therapy?
Is organ function strong enough for the protocol?
Is performance status adequate?
Can the patient handle travel, return visits, and follow-up?
Is the therapy approved care, or still investigational in this setting?
These are the real filters that often decide whether a patient moves forward to screening. NCI’s trial-participation and payment guidance makes clear that trial pathways involve specific rules and planning, not just general interest.
| Screening Factor | CAR-T | TIL | Gene Therapy |
|---|---|---|---|
| Disease fit |
|
|
|
| Prior treatment fit |
|
|
|
| Medical fitness |
|
|
|
| Logistics and follow-up |
|
|
|
Most cell-therapy reviews move faster when the key documents are ready at the start. In practice, these are often the most useful records to prepare first.
- Pathology or diagnostic confirmation
- Recent scans or disease assessment
- Full treatment history in order
- Recent blood counts and chemistry
- Medication list
- Recent hospitalization or complication records
- Referral note summarizing why cell therapy is being considered
Travel and Coordination Questions
Travel is often part of cell-therapy care, especially for trials and specialized centers. That burden may include repeated visits, temporary local stay, caregiver support, and time away from work or school. NCI explains that trial participation can still create costs and planning burdens even when some study-related costs are covered.
A patient-facing page should also say clearly that placement is never guaranteed. Screening failure, manufacturing issues, evolving trial availability, location limits, or medical changes during review can all stop the process before treatment happens. That is one reason this page should point patients toward informed review rather than hype.
Request Trial Matching
A good trial-matching request should do three things clearly:
First, separate approved care now from trial-only care now.
Second, match by disease, prior therapy, organ function, and geography.
Third, show realistic next steps, not just a long list of trials.
That matters because the current cell-therapy landscape is mixed. Some options are already FDA-approved and some are still investigational, and the best next step may be approved care, another trial, or a non-trial specialist consultation depending on the case.
FAQ
How do I find the right cell-therapy trial?
Start by confirming the exact diagnosis, subtype, prior treatment history, and current disease status. Then compare those facts against real trial listings and specialist review, because cell-therapy eligibility is disease-specific and location-specific.
What records should I prepare?
Prepare the diagnosis report, treatment history, recent scans or marrow results, recent labs, medication list, and recent hospitalization records. Those are the documents most likely to help a center decide whether screening makes sense.
How fast can eligibility be checked?
There is no universal timeline. A basic records review can happen earlier, but formal eligibility may take longer because it depends on protocol rules, center capacity, additional testing, and whether the disease is stable enough to wait through screening and treatment planning. This is an inference based on how trial infrastructure and screening work.
Who pays in a trial?
NCI says many trial costs may be covered by the study sponsor, a patient’s insurance, or both, but there can still be out-of-pocket costs. Patients should ask exactly which costs are covered before enrolling.
What happens if I am not eligible?
If a patient is not eligible, the next step may still be approved care, another clinical trial, local standard treatment, or a second-opinion review. Screening failure does not mean there are no options; it means the current protocol is not the right fit. This is a practical inference from how trial pathways and approved-care alternatives coexist in the current FDA/NCI landscape.
Can physicians submit referrals?
Yes, in practice, physicians commonly submit records to specialty or trial centers for review. The exact process varies by center, but referral usually starts with diagnosis confirmation, prior therapy history, and current medical records. This is an inference from standard specialty-center workflows and NCI trial infrastructure.
Clinical Trials:
Medical Disclaimer & Source References
© BEIJING BIOTECH.
Clinical Sources: NCCN, ASCO, ACS, ESMO, CSCO, CACA, ChiCTR.
Clinical Trials: Trial participation depends on inclusion and exclusion criteria, prior treatment, organ function, timing, and location.